D 4418
Latest Information Update: 22 Oct 1998
Price :
$50 *
At a glance
- Originator Celltech Group
- Class Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 22 Oct 1998 Discontinued-I for Asthma in United Kingdom (PO)
- 22 May 1997 Phase-I clinical trials for Asthma in United Kingdom (PO)
- 15 Nov 1996 New profile